Amid ongoing discussions about telehealth regulations post-pandemic, the DEA introduced new rules to ensure patient safety while permitting access to controlled substances. These guidelines aim to maintain some flexibility formed during the pandemic but have incited backlash from telehealth advocates. Key concerns involve proposed regulations regarding in-person visit requirements and a new registration process for clinicians prescribing certain medications, which advocates argue could complicate patient access and diminish the benefits of telehealth access established during the pandemic.
One proposal by the DEA would create a special registration that allows clinicians to prescribe medications via telemedicine, but with significant restrictions.
Telehealth advocates express concern that new DEA proposals could create barriers for patients access to necessary medications.
Collection
[
|
...
]